Head-To-Head Contrast: AnaptysBio (ANAB) vs. Gilead Sciences (GILD)
AnaptysBio (NASDAQ: ANAB) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.
This table compares AnaptysBio and Gilead Sciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares AnaptysBio and Gilead Sciences’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|AnaptysBio||$12.97 million||53.48||-$16.59 million||N/A||N/A|
|Gilead Sciences||$28.47 billion||3.84||$17.97 billion||$9.21||9.08|
Gilead Sciences has higher revenue and earnings than AnaptysBio.
Insider & Institutional Ownership
71.4% of AnaptysBio shares are owned by institutional investors. Comparatively, 74.0% of Gilead Sciences shares are owned by institutional investors. 1.3% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Gilead Sciences pays an annual dividend of $2.08 per share and has a dividend yield of 2.5%. AnaptysBio does not pay a dividend. Gilead Sciences pays out 22.6% of its earnings in the form of a dividend.
This is a breakdown of current ratings and target prices for AnaptysBio and Gilead Sciences, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
AnaptysBio currently has a consensus price target of $37.00, suggesting a potential upside of 8.50%. Gilead Sciences has a consensus price target of $84.62, suggesting a potential upside of 1.20%. Given AnaptysBio’s stronger consensus rating and higher possible upside, equities analysts plainly believe AnaptysBio is more favorable than Gilead Sciences.
Gilead Sciences beats AnaptysBio on 9 of the 13 factors compared between the two stocks.
AnaptysBio Company Profile
AnaptysBio, Inc. is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product pipeline includes ANB020 and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. The Company’s ANB020 product candidate is an antibody that inhibits the activity of interleukin-33, and is used for the treatment of severe adult asthma and severe adult peanut allergy. In addition, the Company is engaged in developing its ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustular psoriasis (PPP).
Gilead Sciences Company Profile
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.
Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.